| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Dipartimento di Oncologia,*
Istituto di
Endocrinologia,
and Dipartimento di
Chirurgia,
Università degli Studi di
Pisa, Pisa; the Istituto Nazionale dei Tumori di
Napoli,
Fondazione Senatore Pascale, Naples;
and Centro di Endocrinologia ed Oncologia Sperimentale del CNR c/o
Dipartimento di Biologia e Patologia Cellulare e
Molecolare,¶
Università di Napoli
"Federico II", Naples, Italy
The tall-cell variant (TCV) of papillary thyroid carcinoma (PTC), characterized by tall cells bearing an oxyphilic cytoplasm, is more clinically aggressive than conventional PTC. RET tyrosine kinase rearrangements, which represent the most frequent genetic alteration in PTC, lead to the recombination of RET with heterologous genes to generate chimeric RET/PTC oncogenes. RET/PTC1 and RET/PTC3 are the most prevalent variants. We have found RET rearrangements in 35.8% of TCV (14 of 39 cases). Whereas the prevalences of RET/PTC1 and RET/PTC3 were almost equal in classic and follicular PTC, all of the TCV-positive cases expressed the RET/PTC3 rearrangement. These findings prompted us to compare RET/PTC3 and RET/PTC1 in an in vitro thyroid model system. We have expressed the two oncogenes in PC Cl 3 rat thyroid epithelial cells and found that RET/PTC3 is endowed with a strikingly more potent mitogenic effect than RET/PTC1. Mechanistically, this difference correlated with an increased signaling activity of RET/PTC3. In conclusion, we postulate that the correlation between the RET/PTC rearrangement type and the aggressiveness of human PTC is related to the efficiency with which the oncogene subtype delivers mitogenic signals to thyroid cells.
This article has been cited by other articles:
 |
|
 |
|
  W.-O. Lui, L. Zeng, V. Rehrmann, S. Deshpande, M. Tretiakova, E. L. Kaplan, I. Leibiger, B. Leibiger, U. Enberg, A. Hoog, et al. CREB3L2-PPAR{gamma} Fusion Mutation Identifies a Thyroid Signaling Pathway Regulated by Intramembrane Proteolysis Cancer Res., September 1, 2008; 68(17): 7156 - 7164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mariggio, B. M. Filippi, C. Iurisci, L. K. Dragani, V. De Falco, M. Santoro, and D. Corda Cytosolic Phospholipase A2{alpha} Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells Cancer Res., December 15, 2007; 67(24): 11769 - 11778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Santoro, R. M. Melillo, and A. Fusco RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Caudill, Z. Zhu, R. Ciampi, J. R. Stringer, and Y. E. Nikiforov Dose-Dependent Generation of RET/PTC in Human Thyroid Cells after in Vitro Exposure to {gamma}-Radiation: A Model of Carcinogenic Chromosomal Rearrangement Induced by Ionizing Radiation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2364 - 2369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Di Cristofaro, V Vasko, V Savchenko, S Cherenko, A Larin, M D Ringel, M Saji, M Marcy, J F Henry, P Carayon, et al. ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients Endocr. Relat. Cancer, March 1, 2005; 12(1): 173 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Russell, J. B. Engiles, and J. L. Rothstein Proinflammatory Mediators and Genetic Background in Oncogene Mediated Tumor Progression J. Immunol., April 1, 2004; 172(7): 4059 - 4067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. French, E. K. Alexander, E. S. Cibas, V. Nose, J. Laguette, W. Faquin, J. Garber, F. Moore Jr, J. A. Fletcher, P. R. Larsen, et al. Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer Am. J. Pathol., April 1, 2003; 162(4): 1053 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Finn, P. Smyth, J. O'Leary, E. C. Sweeney, and O. Sheils Ret/PTC Chimeric Transcripts in an Irish Cohort of Sporadic Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 938 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A. J. Ryan, G. Fontanini, A. Fusco, and M. Santoro ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases Cancer Res., December 15, 2002; 62(24): 7284 - 7290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Collins, G. Chiappetta, A. B. Schneider, M. Santoro, F. Pentimalli, L. Fogelfeld, T. Gierlowski, E. Shore-Freedman, G. Jaffe, and A. Fusco RET Expression in Papillary Thyroid Cancer from Patients Irradiated in Childhood for Benign Conditions J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3941 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Kroll Molecular Rearrangements and Morphology in Thyroid Cancer Am. J. Pathol., June 1, 2002; 160(6): 1941 - 1944. [Full Text] [PDF]
|
|
|
|
|
|
A. Fusco, G. Chiappetta, P. Hui, G. Garcia-Rostan, L. Golden, B. K. Kinder, D. A. Dillon, A. Giuliano, A. M. Cirafici, M. Santoro, et al. Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma : A Search for the Early Precursors of Papillary Cancer Am. J. Pathol., June 1, 2002; 160(6): 2157 - 2167. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
